| __timestamp | MannKind Corporation | Zoetis Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100244000 | 396000000 |
| Thursday, January 1, 2015 | 29674000 | 364000000 |
| Friday, January 1, 2016 | 14917000 | 376000000 |
| Sunday, January 1, 2017 | 14118000 | 382000000 |
| Monday, January 1, 2018 | 8737000 | 432000000 |
| Tuesday, January 1, 2019 | 6900000 | 457000000 |
| Wednesday, January 1, 2020 | 6248000 | 463000000 |
| Friday, January 1, 2021 | 12312000 | 508000000 |
| Saturday, January 1, 2022 | 19721000 | 539000000 |
| Sunday, January 1, 2023 | 31283000 | 614000000 |
| Monday, January 1, 2024 | 686000000 |
Unlocking the unknown
In the ever-evolving landscape of pharmaceutical innovation, research and development (R&D) investments are pivotal. From 2014 to 2023, Zoetis Inc. and MannKind Corporation have demonstrated contrasting strategies in their R&D expenditures. Zoetis Inc., a leader in animal health, consistently increased its R&D spending, peaking at approximately $614 million in 2023, marking a 55% rise from 2014. This steady growth underscores Zoetis's commitment to innovation and market leadership.
Conversely, MannKind Corporation, known for its focus on diabetes and pulmonary diseases, experienced a more volatile R&D investment pattern. Starting with a high of around $100 million in 2014, MannKind's R&D expenses dwindled to a low of $6 million in 2020, before rebounding to $31 million in 2023. This fluctuation reflects the challenges and strategic shifts MannKind faced in its niche market.
These investment trends highlight the diverse approaches companies take in navigating the competitive pharmaceutical industry.
Analyzing R&D Budgets: Zoetis Inc. vs Takeda Pharmaceutical Company Limited
R&D Insights: How Zoetis Inc. and Sarepta Therapeutics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Zoetis Inc. and Halozyme Therapeutics, Inc.
Comparing Innovation Spending: Zoetis Inc. and Ultragenyx Pharmaceutical Inc.
Analyzing R&D Budgets: Zoetis Inc. vs Viking Therapeutics, Inc.
Zoetis Inc. vs ADMA Biologics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Zoetis Inc. and Travere Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Zoetis Inc. and Amphastar Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc vs MannKind Corporation: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Viking Therapeutics, Inc. vs MannKind Corporation
R&D Insights: How PTC Therapeutics, Inc. and MannKind Corporation Allocate Funds
Research and Development Expenses Breakdown: Veracyte, Inc. vs MannKind Corporation